Are You Keeping Tabs on What Management Is Doing With Your Money?

Find out what you can do to keep yourself from staying up at night wondering about what companies like Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) are doing with your hard-earned money.

| More on:

The idea behind making an investment in the equity of a publicly traded company is that you’re essentially handing over your hard-earned capital to the company’s managers, who you are expecting to earn you a fair return on your investment.

But how sure are you that’s what’s happening with the investments you currently own?

Understanding the shareholder-manager agency problem

The shareholder-manager agency problem is a problem that is about as old as capitalism itself.

The problem arises because the shareholders — that would be you as an investor, or the owner of a company — are the one providing the capital, or money, to pay the bills, hire staff, and invest in capital expenses like plants and equipment.

Yet it’s actually not you, but rather the employees, or management, of the company who are actually the ones responsible for making the hiring, firing and investment decisions on a day-to-day basis.

That means it’s up to the owners — and not the senior managers — of the company to ensure that management is making responsible decisions with the profits of the firm.

Let’s take a closer look at the options available to management as to what they are able to do with a firm’s capital and how those decisions can impact shareholder wealth.

Mergers and acquisitions

This is potentially the avenue most fraught with disastrous outcomes. That’s because sometimes managers of a company find themselves incentive to pursue merger and acquisition (M&A) opportunities to meet certain financial targets.

But the problem arises when those managers place undue emphasis on short-term financial incentives, like year-end bonuses, at the expense of more positive long-term shareholder outcomes.

That type of scenario can lead to disastrous investment outcomes. Look no further than the fate that befell Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) as but one recent example of an M&A strategy gone wrong.

Retiring debt obligations

Management can use a firm’s profits to retire outstanding debt obligations; sometimes it makes sense, and in other cases, not so much.

If, on the one hand, your firm (for example, the aforementioned Valeant Pharmaceuticals) has racked up an unsustainable balance of debt, paying down those financial obligations can be the responsible thing to do.

On the other hand, it may raise questions as to how management got themselves in that position in the first place.

In most cases, firms will target what is referred to as an optimal capital structure — or the optimal mix of debt in relation to assets and equity. Allocating capital in this manner can be an indication that management is, in fact, creating shareholder wealth by adding to or subtracting from its liabilities.

Returning profits to shareholders through dividends and buybacks

Paying a healthy and growing dividend has to be the most tried and true — and probably most “fail-safe” — approach to dealing with shareholders’ money in a responsible and sustainable manner.

Returning firm profits via either dividends or buybacks ensures that shareholders have a say on where the money will be directed — either through reinvestment in the firm or otherwise.

Bottom line

The best thing that investors can do for themselves to help mitigate the risk of the shareholder-manager agency problem is to only invest in companies with demonstrable track records of creating shareholder wealth.

Following that simple rule of thumb will help keep you from staying awake at night wondering what those strangers are doing with your money.

Stay Foolish.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jason Phillips has no position in any of the stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Dividend Stocks

Senior Couple Walking With Pet Bulldog In Countryside
Dividend Stocks

CPP Insights: The Average Benefit at Age 60 in 2024

The average CPP benefit at age 60 in average is low, but claiming early has many advantages with the right…

Read more »

thinking
Dividend Stocks

Why Did goeasy Stock Jump 6% This Week?

The spring budget came in from our federal government, and goeasy stock (TSX:GSY) investors were incredibly pleased by the results.

Read more »

woman analyze data
Dividend Stocks

My Top 5 Dividend Stocks for Passive-Income Investors to Buy in April 2024

These five TSX dividend stocks can help you create a passive stream of dividend income for life. Let's see why.

Read more »

investment research
Dividend Stocks

5 Easy Ways to Make Extra Money in Canada

These easy methods can help Canadians make money in 2024, and keep it growing throughout the years to come.

Read more »

Road sign warning of a risk ahead
Dividend Stocks

High Yield = High Risk? 3 TSX Stocks With 8.8%+ Dividends Explained

High yield equals high risk also applies to dividend investing and three TSX stocks offering generous dividends.

Read more »

Dial moving from 4G to 5G
Dividend Stocks

Is Telus a Buy?

Telus Inc (TSX:T) has a high dividend yield, but is it worth it on the whole?

Read more »

Senior couple at the lake having a picnic
Dividend Stocks

How to Maximize CPP Benefits at Age 70

CPP users who can wait to collect benefits have ways to retire with ample retirement income at age 70.

Read more »

Growing plant shoots on coins
Dividend Stocks

3 Reliable Dividend Stocks With Yields Above 5.9% That You Can Buy for Less Than $8,000 Right Now

With an 8% dividend yield, Enbridge is one of the stocks to buy to gain exposure to a very generous…

Read more »